Brokerages Expect SenesTech Inc (SNES) to Announce ($0.19) EPS

SenesTech Inc (NASDAQ:SNES) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus target price of $9.38 for the company and are predicting that the company will post ($0.19) earnings per share for the current quarter, according to Zacks. Zacks has also given SenesTech an industry rank of 185 out of 265 based on the ratings given to its competitors.

A number of analysts recently issued reports on the company. ValuEngine raised SenesTech from a “strong sell” rating to a “sell” rating in a research report on Friday. Zacks Investment Research raised SenesTech from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. Craig Hallum set a $3.00 price objective on SenesTech and gave the company a “buy” rating in a research note on Wednesday, November 22nd. Finally, Roth Capital reduced their price objective on SenesTech from $3.75 to $14.00 and set a “buy” rating for the company in a research note on Thursday, December 28th.

Shares of SenesTech (NASDAQ SNES) remained flat at $$0.68 during midday trading on Tuesday. 16,816 shares of the stock traded hands, compared to its average volume of 246,969. The stock has a market capitalization of $10.80 and a price-to-earnings ratio of -0.51. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.67 and a current ratio of 2.94. SenesTech has a 52-week low of $0.56 and a 52-week high of $9.60.

SenesTech (NASDAQ:SNES) last announced its earnings results on Wednesday, November 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.25 million. SenesTech had a negative return on equity of 190.41% and a negative net margin of 14,473.40%. research analysts predict that SenesTech will post -1.16 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Skylands Capital LLC raised its stake in SenesTech by 140.1% during the 4th quarter. Skylands Capital LLC now owns 210,017 shares of the company’s stock valued at $151,000 after acquiring an additional 122,534 shares during the last quarter. TCI Wealth Advisors Inc. purchased a new position in shares of SenesTech during the 3rd quarter worth approximately $748,000. Gilder Gagnon Howe & Co. LLC raised its stake in shares of SenesTech by 32.1% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 1,424,173 shares of the company’s stock worth $1,025,000 after buying an additional 345,674 shares in the last quarter. Finally, Prudential PLC raised its stake in shares of SenesTech by 49.3% during the 2nd quarter. Prudential PLC now owns 447,971 shares of the company’s stock worth $2,661,000 after buying an additional 147,971 shares in the last quarter. 15.28% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Brokerages Expect SenesTech Inc (SNES) to Announce ($0.19) EPS” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/02/brokerages-expect-senestech-inc-snes-to-announce-0-19-eps.html.

SenesTech Company Profile

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.

Get a free copy of the Zacks research report on SenesTech (SNES)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply